Trinity Biotech CGM+ Biosensor Targets False Glucose Alerts

Trinity Biotech's CGM+ Wearable Biosensor Demonstrates Nocturnal Compression Detection in Clinical Study

DUBLIN, Ireland — July 31, 2026 — Trinity Biotech plc, a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, has released clinical study results confirming that its next-generation CGM+ wearable biosensor platform can detect nocturnal compression-induced false low glucose events — a persistent and clinically significant limitation of conventional continuous glucose monitoring (CGM) systems.

The announcement, which drove Trinity Biotech's shares up 36.07% to close at $12.45 on July 28, 2026, marks a meaningful technical milestone for the company as it advances the CGM+ platform toward pivotal clinical trials and subsequent regulatory submission.

Main Development

Compression-related false low glucose alarms are a well-documented source of inaccurate CGM alerts, particularly during sleep, when patients may inadvertently compress the sensor against a surface. These false readings can trigger unnecessary interventions and erode patient confidence in wearable monitoring technology.

Trinity Biotech's clinical study demonstrated that the CGM+ platform incorporates a purpose-built capability to identify and differentiate these compression-induced artifacts from genuine hypoglycemic events. The company stated it intends to integrate this nocturnal compression low detection feature into the platform ahead of its pivotal clinical trial phase and subsequent regulatory filing.

The development comes as the broader biosensors market continues to expand rapidly, driven by rising chronic disease prevalence, growing demand for home-care diagnostics, and accelerating innovation in wearable sensor technology. According to Next Move Strategy Consulting, the global biosensors market was valued at USD 27.15 billion in 2023 and is projected to reach USD 48.66 billion by 2030, advancing at a compound annual growth rate (CAGR) of 8.7% over the forecast period.

Separately, on July 24, 2026, Trinity Biotech implemented a one-for-thirty reverse ADS split to regain compliance with the Nasdaq minimum bid price requirement of $1.00.

Key Highlights:

• Trinity Biotech's CGM+ wearable biosensor platform successfully demonstrated the ability to detect nocturnal compression-induced false low glucose events in a clinical study setting.

• The company plans to incorporate this differentiated detection capability into the CGM+ platform ahead of pivotal clinical trials and regulatory submission.

• Compression-related false low glucose alarms represent a common and clinically disruptive limitation of conventional CGM systems, and the CGM+ platform's capability directly addresses this gap.

Analyst Insight:

According to analysts at Next Move Strategy Consulting, the biosensors market is experiencing sustained momentum driven by the increasing adoption of wearable diagnostic devices across home healthcare and point-of-care settings. The growing prevalence of diabetes globally — a primary demand driver for continuous glucose monitoring technologies — continues to accelerate investment in next-generation biosensor platforms. Innovations that address real-world accuracy limitations, such as compression artifact detection, are expected to be critical differentiators as the market moves toward regulatory-grade wearable diagnostics integrated within Internet of Medical Things (IoMT) ecosystems. North America currently holds the largest share of the global biosensors market, supported by the presence of major industry players including Abbott Laboratories, Dexcom Inc., and Medtronic, all of which are actively expanding their glucose monitoring portfolios.

Industry Outlook:

The biosensors sector is entering a phase of accelerated clinical validation, with multiple platforms — including Trinity Biotech's CGM+ — progressing toward pivotal trials and regulatory submissions. As wearable biosensors become more deeply embedded in chronic disease management protocols, the ability to deliver clinically reliable, artifact-free data will be a defining competitive advantage. Regulatory agencies, including the U.S. FDA, have demonstrated increasing receptivity to over-the-counter and prescription-free biosensor platforms, as evidenced by recent clearances in the continuous glucose monitoring space. Analysts expect the convergence of artificial intelligence, advanced materials science, and miniaturized sensor architectures to further expand the addressable market for biosensors across medical diagnostics, environmental monitoring, and food safety applications through 2030 and beyond.

Source: RTTNews

For More Information – Download FREE Sample on Biosensors Market Report

Prepared By: Sanyukta Deb